About BIOS

The Johns Hopkins Brain Injury Outcomes (BIOS) Division is a clinical trial coordinating center (data management center, imaging reading center, and enrollment center) within the Johns Hopkins School of Medicine Department of Neurology. Its focus is to provide multicenter management to clinical trials evaluating therapeutic, preventive and diagnostic interventions. Led by Dr. Daniel F. Hanley, BIOS has unique expertise in the coordination and management of trials investigating rare neurologic disorders, acute neurologic ICU conditions, rehabilitation, and functional outcomes. Since the 1990s, BIOS has coordinated international, federally funded and industry-sponsored trials across a wide range of conditions for investigators within the JHU departments of Neurology, Neurosurgery, Anesthesiology/Critical Care Medicine, Hematology and Neuroradiology, as well as for investigators at other academic centers around the U.S.

 Read More

Johns Hopkins-Tufts TIC

BIOS and the Johns Hopkins Institute for Clinical and Translational Research (ICTR) have been awarded a seven-year, $25 million grant from the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) to form, along with Tufts University School of Medicine, one of three Trial Innovation Centers (TICs).

The goal of the centers is to promote innovations in the efficiency and quality of NIH-funded trials. The centers are part of the NCATS Trial Innovation Network and will work with the national Clinical and Translational Science Awards Program, which funds a consortium of 64 medical research institutions in 31 states and the District of Columbia. The centers will help the institutions form a long-standing infrastructure for multicenter studies to be funded by NIH and other funding agencies.

 Read More


European Stroke Organisation

Professor Hanley presented the main results of the MISTIE-III trial, an RCT testing minimally invasive catheter evacuation of intracerebral haematoma, aided by local infiltration of alteplase (up to 9 x 1mg doses, 8h apart) with the aim of decreasing clot size to 15 mL or less, against standard medical management.  Read More

The Lancet

Acute stroke due to supratentorial intracerebral haemorrhage is associated with high morbidity and mortality. Open craniotomy haematoma evacuation has not been found to have any benefit in large randomised trials. We assessed whether minimally invasive catheter evacuation followed by thrombolysis (MISTIE), with the aim of decreasing clot size to 15 mL or less, would improve functional outcome in patients with intracerebral haemorrhage.  Read More

EurekAlert! The Global Source for Science News

Aggressive clearance key to best outcome after a brain hemorrhage. MISTIE III trial confirms need to remove at least 70 percent of an intracerebral clot.  Read More

Recent Publications

Surgical performance determines functional outcome benefit in the MISTIE procedure.
Awad IA, Polster SP, Carrión-Penagos J, et al. Neurosurgery. 2019;84(6):1157-68.

Read Article

Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial.
Hanley DF, Thompson RE, Rosenblum M, et al. Lancet. 2019;393(10175):1021-32.

Read Article

Enhancing the informed consent process using shared decision making and consent refusal data from the CLEAR III trial.
Porter AL, Ebot J, Lane K, et al. Neurocritical Care. 2019 September 30.

Read Article

Intensive blood pressure reduction and perihematomal edema expansion in deep intracerebral hemorrhage.
Leasure AC, Qureshi AI, Murthy SB, et al. Stroke. 2019;50(8):2016-22.

Read Article